Novartis Says Chair Contradicted Admissions In FCA Deal

By Adam Lidgett · March 26, 2021, 8:08 PM EDT

Novartis said its chairman incorrectly contradicted the company's admissions that it made as part of a $678 million deal with the federal government to settle claims it flouted the False Claims...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

United States Of America v. Novartis Pharmaceuticals Corporation

Case Number

Court

New York Southern

Nature of Suit

Other Statutory Actions

Date Filed

January 05, 2011

Recent Articles By Adam

November 18, 2024
Medical Group Wants Justices To Review IP Safe Harbor Fight
November 01, 2024
Jury To Decide Timing Issue In Insulin Patch Trade Secret Row
October 22, 2024
Patent Office Finds Public Engagement Leader
September 23, 2024
Fed. Circ. OKs Novartis Loss In Eye Syringe Patent Feud
July 11, 2024
Senate Clears Patent Bill Aiming To Lower Drug Prices
June 07, 2024
DC Circ. Undoes Library Of Congress Win In Fair Use Fight
June 06, 2024
8th Circ. Affirms Cigna Noncompete Applies To CVS Hire
May 29, 2024
Greenberg Traurig Adds IP Atty From Eversheds Sutherland
May 20, 2024
Judge Tosses Acuitas' COVID Biotech IP Suit
April 30, 2024
FTC Continues To Target 'Junk' Drug Patents